Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555297 | 0.88 | LRRK2 (0.36) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL25173938 | 0.83 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL20555353 | 0.83 | GPR35 (0.38) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL15528516 | 0.80 | LMNA (0.36) | ALDH1A1MAPTPKMLMNATHRB | |
| SCHEMBL4559487 | 0.79 | MAPT (0.39) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL15528514 | 0.78 | MCOLN3 (0.34) | ALDH1A1L3MBTL1POLBMAPTKMT2A | |
| SCHEMBL15528517 | 0.78 | MCOLN3 (0.34) | ALDH1A1L3MBTL1POLBMAPTKMT2A | |
| SCHEMBL4561198 | 0.78 | GPR35 (0.37) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL20555048 | 0.78 | L3MBTL1 (0.35) | ALDH1A1L3MBTL1POLBMAPTGPR35 | |
| SCHEMBL15528217 | 0.78 | L3MBTL1 (0.40) | ALDH1A1L3MBTL1POLBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844652-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844652-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164321-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | ALDH1A1 3846/4885L3MBTL1 828/4885POLB 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.